Статья
ВТОРИЧНАЯ ЛЕГОЧНАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ ПРИ СИСТЕМНЫХ ЗАБОЛЕВАНИЯХ СОЕДИНИТЕЛЬНОЙ ТКАНИ
Приводятся современное определение легочной артериальной гипертензии (ЛАГ), данные о распространенности и встречаемости вторичной ЛАГ при системных заболеваниях соединительной ткани (СЗСТ), в том числе на основе регистров США, Франции и Шотландии. Описаны основные звенья патогенеза, классификационный подход, клиника и этапы диагностики.
1. McLaughlin V.V., Presberg K.W., Doyle R.L. et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinic practice guidelines. Chest 2004;126(1 Suppl):78S–92S.
2. Galie N., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25(24):2243-78.
3. Hatano S., Strasser T. World Health Organization 1975 primary pulmonary hypertension. Geneva: WHO; 1975.
4. Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):40S–7.
5. D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343–9.
6. Murata I., Kihara H., Shinohara S., Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 1992;56(10):983-91.
7. Rayner C.F., Grubnic S. Pulmonary manifestations of systemic autoimmune disease. Best Pract Res Clin Rheumatol 2004;18(3):381-410.
8. Battle R.W., Davitt M.A., Cooper S.M. et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110(6):1515-9.
9. Mukherjee D., St George D., Knight C. et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004;43(4):461-6.
10. Mukherjee D., St George D., Coleiro B. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of registry approach. Ann Rheum Dis 2003;62(11):1088-93.
11. Wigley F.M., Lima J.A., Mayes M. et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of communitybased rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52(7):2125- 32.
12. Hachulla E., Gressin V., Guillevin L. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52(12):3792–800.
13. Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023–30.
14. Kumar U., Ramteke R., Yadav R. et al. Prevalence and Predictors of Pulmonary Artery Hypertension in Systemic Sclerosis. J Assoc Physicians India 2008;56:413-7.
15. Dawson J.K., Goodson N.G., Graham D.R., Lynch M.P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000;39(12):1320-5.
16. Asherson R.A., Cervera R. Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol 2007;32(2):153-8.
17. Shen J.Y., Chen S.L., Wu Y.X. et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999;18(4):147-51.
18. Humbert M. The burden of pulmonary hypertension. Eur Respir J 2007;30(1):1-2.
19. Pietra G.G., Capron F., Stewart S. et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):25S–32.
20. Morrell N.W. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006;3(8):680–6.
21. Jing Z.C., Xu X.Q., Han Z.Y. et al. Registry and survival in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132(2):373–9.
22. Rubin L.J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):4S-6S.
23. Cool C.D., Kennedy D., Voelkel N.F., Tuder R.M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997;28(4):434-42.
24. Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия. М.: Нолидж; 1999.
25. Черняев А.Л., Самсонова М.В. Патогенез и патологическая анатомия первичной легочной гипертонии. Болезни сердца и сосудов 2006;1(1):54-9.
26. Edwards W.D., Edwards J.E. Clinical primary pulmonary hypertension: three pathologic types. Circulation 1977;56(5):884-9.
27. Yousem S.A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21(5):467-74.
28. Fagan K.A., Badesch D.B. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002;45(3):225-34.
29. Quismoro F.P. Jr, Sharma O., Koss M. et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984;13(4):349-59.
30. Eddahibi S., Morrell N., d'Ortho M.P., Naeije R., Adnot S. Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002;20(6):1559-72.
31. Li E.K., Tam L.S. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999;26(9):1923-9.
32. Stupi A.M., Steen V.D., Owens G.R. et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29(4):515-24.
33. Ueda N., Mimura K., Maeda H. et al. Mixed connective tissue disease with fatal pulmonary hypertension and review of literature. Virchows Arch A Pathol Anat Histopathol 1984;404(4):335-40.
34. Fahey P.J., Utell M.J., Condemi J.J., Green R., Hyde R.W. Raynaud's phenomenon of the lung. Am J Med 1984;76(2):263-9.
35. Von Euler U., Lijestrand G. Observations on the pulmonary arterial blood pressure in cat. Acta Physiol Scand 1946;12:301–20.
36. Archer S., Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000;102(22):2781-91.
37. Barnes P.J., Kharitonov S.A. Exhaled nitric oxide: a new lung function test. Thorax 1996;51(3):233–7.
38. Belvisi M.G., Barnes P.J., Larkin S. et al. Nitric oxide synthase activity is elevated in inflammatory lung diseases. Eur J Pharmacol 1995;283(1-3):255-8.
39. Thomas S.R., Kharitonov S.A., Scott S.F., Hodson M.E., Barnes P.J. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest 2000;117(4):1085-9.
40. Rolla G., Colagrande P., Scappaticci E. et al. Exhaled nitric oxide in systemic sclerosis: relationship with lung involvement and pulmonary hypertension. J Rheumatol 2000;27(7):1693-8.
41. Насонов Е.Л., Баранов А.А., Саложин К.В. Лабораторная диагностика системных васкулитов. В Насонов Е.Л., Баранов А.А., Шилкина Н.П., редакторы. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. С. 173-245.
42. Blann A.D., Hopkins J., Winkles J., Wainwright A.C. Plasma and serum Von Willebrand factor antigen concentration in connective tissue disorders. Ann Clin Biochem 1992;29 (Pt 1):67-71.
43. Grassi W., Medico P.D., Izzo F., Cervini C. Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum 2001;30(6):397-402.
44. Krowka M.J., Swanson K.L., Frantz R.P. et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006;44(6):1502–10.
45. Hatano S., Strasser T. Primary pulmonary hypertension: a report on a WHO meeting. Geneva: WHO; 1973.
46. Fuster V., Steele P.M., Edwards W.D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580–7.
47. Dresdale D.T., Schultz M., Michtom R.J. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11(6):686–705.
48. Rich S., Danzker D.R., Ayres S.M. et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107(2):216–223/
49. Шиллер Н., Осипов М.А. Клиническая эхокардиография, 2-е изд. М.: Практика; 2005.
50. McGoon M., Gutterman D., Steen V. et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):14S-34S.
51. Mereles D., Grunig E. A stepwise and practical approach to optimizing echocardiography in pulmonary hypertension. Advances in Pulmonary Hypertension 2006;5(3):30–3.
52. Hinderliter A.L., Willis R. W. 4th, Barst R. J. et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 1997;95(6):1479–86.
53. Arcasoy S. M., Christie J. D., Ferrary V. A. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167(5):735–40.